| Literature DB >> 2899662 |
M S Horowitz1, C Rooks, B Horowitz, M W Hilgartner.
Abstract
The safety of an antihaemophilic factor concentrate treated with the organic solvent tri-(n-butyl)phosphate and sodium cholate (factor VIII-SD) was assessed for transmission of non-A, non-B (NANB) hepatitis and human immunodeficiency virus (HIV). Patients enrolled in the study had no previous exposure to blood products made from plasma pools, although 5 had received small quantities of single-donor products. All but 1 had normal alanine aminotransferase (ALT) levels, none had markers of HIV infection, and all had been vaccinated against hepatitis B. After treatment with factor VIII-SD, serum ALT levels and HIV antibody were monitored for up to 1 year. 20 patients received 625 to greater than 40,000 U (total 163,000 U, median dose 3900 U), and 17 of these were followed up for at least 6 months: transmission of either NANB hepatitis or HIV was not observed.Entities:
Mesh：
Substances：
Year: 1988 PMID： 2899662 DOI： 10.1016/s0140-6736(88)92288-x
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321